

ATTY. DOCKET NO.

4-21233A

APPLICATION NO.

09/367,361

APPLICANT

Burkhard Schütemann


FILING DATE

AUGUST 11, 1999

Group
1615

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
JS	AA	* 4,945,149	7/31/90	Matsumoto et al.			
JS	AB	* 4,897,270	1/30/90	Deutsch et al.			
	AC	* 5,840,335	11/24/98	Wenzel et al. (English Equivalent to DE 3932987)			
	AD	* 4,857,336	8/15/89	Khanna et al.			
	AE	* 5,231,089	7/27/93	Bodor			
	AF	* 5,476,654	12/19/95	Conte et al.			
JS	AG	* 4,452,738	6/5/84	Aufderhaar			
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
JS	AM	835,956	5/25/60	GB			<input type="checkbox"/>	<input type="checkbox"/>
JS	AN	907,309	10/3/62	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AO	2 195 248	4/7/88	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/32183	5/10/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
JS	AQ	EP 0 435 826	12/18/90	EPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JS	AR	Austria-Codex Fachinformation 1995/96 (for Trileptal)
JS	AS	Appel L. E. et al., "Formulation and Optimization of a Modified Microporous Cellulose Acetate Latex Coating for Osmotic Pumps," Pharmaceutical Research, Vol. 9, No. 12, pp. 1664-1667 (1992)
JS	AT	Bodmeier R. et al., "Constant Potassium Chloride Release from Microporous Membrane-Coated Tablets Prepared with Aqueous Colloidal Polymer Dispersions," Pharmaceutical Research, Vol. 8, No. 3 (1991)

EXAMINER

JAMES M. Spear

DATE CONSIDERED

03-05-2005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

Use several sheets if necessary)

ATTY. DOCKET NO.

4-21233A

APPLICATION NO.


09/367,361

APPLICANT

Burkhard Schlötermann

FILING DATE

AUGUST 11, 1999

Group
1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JS	DA	CA129:180164, Schlötermann, WO9835681, abstract No Date
↑	DB	Degen, P.H. et al., "The Influence of Food on the Disposition of the Antiepileptic Oxcarbazepine and its Major Metabolites in Healthy Volunteers," Biopharmaceutics & Drug Disposition, Vol. 15(6), pp. 519-526, (1994)
	DC	Fassihi A.R. et al., "Dissolution of Theophylline from Film-coated Slow Release Mini-tablets in Various Dissolution Media," J. Pharm. Pharmacol., Vol. 41, pp. 369-372 (1989)
	DD	Hell Jung et al., "Influence of food on bioavailability of carbazepine," Pharmaceutical Research, Vol. 11(10) Supl., p. s219 (1994)
	DE	Lindholm T. et al., "Polysorbate 20 as a drug release regulator in ethyl cellulose film coatings," J. Pharm. Pharmacol. Vol. 38, pp. 686-688 (1986)
	DF	McLean M.J., "Oxcarbazepine: Mechanisms of Action," Epilepsia, Vol. 35, S5-S9 (1994)
	DG	Parikh N.H. et al., "Aqueous Ethylcellulose Dispersion of Ethylcellulose. I. Evaluation of Coating Process Variables," Pharmaceutical Research, Vol. 10, No.4, pp. 525-534 (1993)
↓	DH	Porter S.C. et al., "The permeability of enteric coatings and the dissolution rates of coated tablets," J. Pharm. Pharmacol., Vol. 34, pp. 5-8 (1982)
JS	DI	Schwabe S., "Clinical Development Outlook of Oxcarbazepine," Epilepsia, Vol. 35, S2-S4 (1994)
	DJ	Notice of Opposition against European Patent No. EP 0 966 287 B1 (European Application No. 98908091.6) entitled "Oxcarbazepine Film-Coated Tablets" in the name of and on behalf of Technimedica Sociadada, February 4, 2004
	DK	Notice of Opposition against European Patent No. EP 0 966 287 (European Application No. 98908091.6 entitled Oxcarbazepine Film-Coated Tablets" in the name of Generics (UK) Limited, February 9, 2004
	DL	Notice of Opposition against European Patent No. EP 0 966 287 (European Application No. 98908091.6 entitled Oxcarbazepine Film-Coated Tablets" in the name of Taro Pharmaceuticals, Inc., February 6, 2004
JS	DM	M. Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics, 4 th Edition, Lea & Febiger, Philadelphia, page 51, (1991)
JS	DN	G.S. Banker, C.T. Rhodes, Marcel Dekker, Modern Pharmaceuticals, pp. 133, 335, 336, 3 rd Edition, New York, (1995)

EXAMINER

JAMES M. Spear

DATE CONSIDERED

03-05-2005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

4-21233A

APPLICATION NO.

09/367,361

APPLICANT

Burkhard Schlottermann

FILING DATE

AUGUST 11, 1999

Group
1615



FOREIGN PATENT DOCUMENTS

INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
JS	CA	IE 904685 (English Language Equivalent to EP 0 435	12/21/96	Ireland	—	—	<input type="checkbox"/>	<input type="checkbox"/>
JS	CB	1 310 120	3/14/73	Great Britain	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	CC						<input type="checkbox"/>	<input type="checkbox"/>
	CD						<input type="checkbox"/>	<input type="checkbox"/>
	CE						<input type="checkbox"/>	<input type="checkbox"/>
	CF						<input type="checkbox"/>	<input type="checkbox"/>
	CG						<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER
JAMES M. Spear

DATE CONSIDERED
03-05-2005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

4-21233A

APPLICATION NO.

09/367,361

APPLICANT

Burkhard Schlötermann

FILING DATE

AUGUST 11, 1999

Group

1615



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

js	DA	Remington, "The Science and Practice of Pharmacy", 19 th Edition, pp. 1449, (1995)
↑	DB	Extract from M-Tec website No Date
↓	DC	SPC for Trileptal Available from the eMC No Date
↓	DD	N. Kitamori, "Effect of Drug Content and Drug Particle Size on the Change in Particle Size During Tablet Compression", J. Pharm. Pharmacol. Vol. 31, pp. 505-507, (1979)
js	DE	S.H. Yalkowsky, S. Bolton, "Particle size and Content Uniformity", Pharmaceutical Research Vol. 7, pp. 962-966 No Date
	DF	Declaration of Raj Suryanarayanan regarding EP 0 966 287
	DG	Curriculum Vitae of Raj Suryanarayanan
	DH	Declaration of Mohammed Safadi
	DI	Curriculum Vitae of Muhammed Safadi
js	DJ	M. Dam et al. Euro. J. of Clin. Pharmacol, Vol. 2, pp. 59-64, (1981)
↑	DK	M. Dam and P. Jensen, Antiepileptic Drugs, 3 rd Edition, Chapter 66, pp. 913-924, (1989)
↓	DL	Raj Suryanarayanan, Powder Diffraction, Vol. 5, No. 3, pp. 155-159, (1990)
↓	DM	Noyes and Whitney, JACS, Vol. 19, pp. 930-932, (1897)
js	DN	Translation of the relevant parts of Rudolf Voigt, Lehrbuch der pharmazeutischen Technologie, 6 th edition, pp 635-638 No Date

EXAMINER

James M. Spear


DATE CONSIDERED

03-05-2005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-21233A
APPLICATION NO.
09/367,361
APPLICANT
Burkhard Schlötermann
FILING DATE
AUGUST 11, 1999

Sheet 5 of 5

Group
1615

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JS	DA	Trileptal Basic Drug Information issued March 24, 1993 (19 pages)
JS	DB	English Translation of WO94/15610 (4 pages) <i>No Date</i>
JS	DC	Report B 84/1989 dated October 3, 1989 (2 pages)
JS	DD	Clinical Pharmacology Report No. 47680 02 029, dated July 17 1998 (4 pages)
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

JAMES M. SPEAR

DATE CONSIDERED

03-05-2005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.